Literature DB >> 11844663

Amide derivatives of meclofenamic acid as selective cyclooxygenase-2 inhibitors.

Amit S Kalgutkar1, Scott W Rowlinson, Brenda C Crews, Lawrence J Marnett.   

Abstract

This paper describes SAR studies involved in the transformation of the NSAID meclofenamic acid into potent and selective cyclooxygenase-2 (COX-2) inhibitors via neutralization of the carboxylate moiety in this nonselective COX inhibitor.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11844663     DOI： 10.1016/s0960-894x(01)00792-2

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  13 in total

1.  QSAR and classification models of a novel series of COX-2 selective inhibitors: 1,5-diarylimidazoles based on support vector machines.

Authors:  H X Liu; R S Zhang; X J Yao; M C Liu; Z D Hu; B T Fan
Journal:  J Comput Aided Mol Des       Date:  2004-06       Impact factor: 3.686

2.  Modifications of diflunisal and meclofenamate carboxyl groups affect their allosteric effects on GABAA receptor ligand binding.

Authors:  Mikko Uusi-Oukari; Laura Vähätalo; Arto Liljeblad
Journal:  Neurochem Res       Date:  2014-06-13       Impact factor: 3.996

3.  Antitumor effect of meclofenamic acid on human androgen-independent prostate cancer: a preclinical evaluation.

Authors:  Alejandro D Soriano-Hernández; Hector R Galvan-Salazar; Daniel A Montes-Galindo; Alejandrina Rodriguez-Hernandez; Rafael Martinez-Martinez; Jose Guzman-Esquivel; Laura L Valdez-Velazquez; Luz M Baltazar-Rodriguez; Francisco Espinoza-Gómez; Augusto Rojas-Martinez; Rocio Ortiz-Lopez; Rafael Gonzalez-Alvarez; Ivan Delgado-Enciso
Journal:  Int Urol Nephrol       Date:  2011-06-10       Impact factor: 2.370

Review 4.  New NSAID targets and derivatives for colorectal cancer chemoprevention.

Authors:  Heather N Tinsley; William E Grizzle; Ashraf Abadi; Adam Keeton; Bing Zhu; Yaguang Xi; Gary A Piazza
Journal:  Recent Results Cancer Res       Date:  2013

5.  Free energy perturbation approach to the critical assessment of selective cyclooxygenase-2 inhibitors.

Authors:  Hwangseo Park; Sangyoub Lee
Journal:  J Comput Aided Mol Des       Date:  2005-01       Impact factor: 3.686

6.  A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity.

Authors:  Gary A Piazza; Adam B Keeton; Heather N Tinsley; Bernard D Gary; Jason D Whitt; Bini Mathew; Jose Thaiparambil; Lori Coward; Gregory Gorman; Yonghe Li; Brahma Sani; Judith V Hobrath; Yulia Y Maxuitenko; Robert C Reynolds
Journal:  Cancer Prev Res (Phila)       Date:  2009-05-26

7.  Synthesis, anti-inflammatory, bactericidal activities and docking studies of novel 1,2,3-triazoles derived from ibuprofen using click chemistry.

Authors:  Kishore Kumar Angajala; Sunitha Vianala; Ramesh Macha; M Raghavender; Murali Krishna Thupurani; P J Pathi
Journal:  Springerplus       Date:  2016-04-11

8.  A tale of switched functions: from cyclooxygenase inhibition to M-channel modulation in new diphenylamine derivatives.

Authors:  Asher Peretz; Nurit Degani-Katzav; Maya Talmon; Eyal Danieli; Anna Gopin; Eti Malka; Rachel Nachman; Amiram Raz; Doron Shabat; Bernard Attali
Journal:  PLoS One       Date:  2007-12-26       Impact factor: 3.240

9.  Virtual screening for novel COX-2 inhibitors using the ZINC database.

Authors:  Kotaprolu Naga Sudha; Mohammed Shakira; Paturi Prasanthi; Nalla Sarika; Ch Narasimha Kumar; Padavala Ajay Babu
Journal:  Bioinformation       Date:  2008-05-13

10.  Prospective performance evaluation of selected common virtual screening tools. Case study: Cyclooxygenase (COX) 1 and 2.

Authors:  Teresa Kaserer; Veronika Temml; Zsofia Kutil; Tomas Vanek; Premysl Landa; Daniela Schuster
Journal:  Eur J Med Chem       Date:  2015-04-08       Impact factor: 6.514
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.